BioMed X, Boehringer Ingelheim partner for psychiatric treatments
The goal is to identify the brain circuits that are maladaptive, potentially developing new treatment approaches for psychiatric illnesses. This project will be complementary to the current psychiatric disease research and development efforts at Boehringer Ingelheim.
“Our scientists will work closely with the new team we are establishing with our partner BioMed X, thereby further supporting our ambition to be an innovation leader in psychiatric diseases,” Christian Tidona, founder and managing director of BioMed X, said. “With this new neuroscience research group, our center is growing to over 60 top researchers from around the world. We are excited about our strong partnership with Boehringer Ingelheim, which is driven by scientific excellence and mutual trust.”
This is the second crowdsourcing project from BioMed X and Boehringer Ingelheim. It is built on the earlier success of another project, which was dedicated to the epigenetic drivers behind COPD.
“We are excited about applying the innovative approach of crowdsourcing to harness the creativity of the scientific community and combine it with our internal research and development capabilities, to discover the next generation of medicines for patients with psychiatric diseases who currently have insufficient treatment options,” Clive Wood, corporate senior vice president and head of discovery research for Boehringer Ingelheim, said.
Organizations in this story
Boehringer-Ingelheim 900 Ridgebury Rd Ridgefield, CT - 06877